Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Xenon Pharmaceuticals Inc. (XENE) had Stock-Based Compensation of $39.59M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-90.90M |
|
-- |
|
-- |
|
$96.34M |
|
$-96.34M |
|
$6.12M |
|
$-90.22M |
|
$-90.22M |
|
$-90.90M |
|
$-90.90M |
|
$-90.90M |
|
$-90.90M |
|
$-96.34M |
|
$-95.69M |
|
79.25M |
|
79.25M |
|
$-1.15 |
|
$-1.15 |
|
| Balance Sheet Financials | |
$480.14M |
|
$8.89M |
|
$127.70M |
|
$607.84M |
|
$38.34M |
|
-- |
|
$9.99M |
|
$48.33M |
|
$559.51M |
|
$559.51M |
|
$559.51M |
|
77.12M |
|
| Cash Flow Statement Financials | |
$-197.64M |
|
$155.30M |
|
$3.58M |
|
$142.71M |
|
$104.51M |
|
$-38.20M |
|
|
Stock-Based Compensation |
$39.59M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.52 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-198.12M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-16.25% |
|
-16.25% |
|
-14.95% |
|
-16.25% |
|
$7.26 |
|
$-2.50 |
|
$-2.49 |
|